绥美凯价格贵吗

The main ingredient of Suimeikai (Doted Abalamid Tablets) is Doptabalamid. This product is a film-coated tablet that appears white or off-white after the coating is removed. It is also recommended that Suimeikai (Doteta Abalami Tablets) is not suitable for long-term use. Generally speaking, if there is still no effect after taking this product for a week, you should stop using it. If the effect is good, you should use it under the guidance of a doctor to achieve the purpose of medication safety. Today let’s take a closer look at Suimeikai. Is it expensive?

Regarding the price of Suimeikai (Doteta abalamib tablets), the original drug is relatively expensive in China. Suimeikan available in China is relatively expensive and most patients cannot afford it. The domestic price of Suimeikan is 2880$/month. Suimeikai, produced by the Indian company Emcure, comes in a box of 30 tablets and sells for about RMB 1,000. Due to the floating exchange rate, the price cannot be determined. Please consult Medical Travel for specific prices.

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation Trimeq (dolute abalamib tablets) with the new generation integrase inhibitor dolutegravir (DTG) as the core for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

Trimicay (dolutegravir) is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment plan of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014.

Suimeike (dolute abalamib tablets) has strong competitiveness in the market: on the one hand, it combines several anti-HIV drugs with different mechanisms to achieve a combined treatment effect; on the other hand, it is convenient to take, which greatly increases the patient's compliance with taking the drug, makes it easier to be accepted by the patient, and reduces the impact of the patient's inability to take the drug on time and in the dose.

Suimeike (dolute abalamide tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

The above is the price content of Suimeikai (Doteta Abalamid Tablets), I hope it can help you!